Optimi Health Completes Production Batch Supplying Phase 2 MDD Trial and Australian Commercial Supply
OPTH sits 26% above its 52-week low of $4.
Summary
Optimi Health completed a cGMP production batch of 5mg psilocybin capsules that will supply both its Phase 2 MDD trial and Australian commercial clinics, with the trial expanded to up to 200 participants.
Key Events · Product Development and Regulatory · OPTH
-
Production Batch Completed
Optimi completed and quality-released a cGMP batch of 5mg psilocybin capsules manufactured in-house under its Health Canada Drug Establishment Licence.
-
Dual Supply for Trial and Commercial
The same batch will supply the Phase 2 MDD trial and commercial Australian clinics, using identical formulation and Chemistry, Manufacturing and Controls data.
-
Phase 2 Trial Expanded
The Health Canada-authorized Phase 2 MDD trial is now a multisite, open-label study of up to 200 participants, with dosing expected to complete by end of 2027.
-
Commercial Safety Record
No serious adverse events reported since commercial supply began in 2025, with over 750 clinicians certified in psychedelic-assisted therapies.
Analysis · OPTH · Life Sciences
Optimi Health has completed and quality-released a cGMP production batch of 5mg psilocybin capsules that will supply both its Health Canada-authorized Phase 2 MDD trial and commercial Australian clinics. This is a meaningful operational milestone because it demonstrates the company can manufacture, encapsulate, and release-test the same formulation for both clinical and commercial use under one licence — a key step toward building the evidentiary base for regulatory registration. The trial has also been expanded to up to 200 participants, with dosing expected to complete by end of 2027. Against the backdrop of a $5.7 million quarterly net loss and a $100 million equity line of credit, this progress on the clinical and commercial front is a positive development, though the company still has no market authorization from Health Canada.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1605 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OPTH was trading at $5.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $28.8M. The 52-week trading range was $4.00 to $8.84. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.